BMC Endocr Disord

GLP-1 RAs effective in managing post-bariatric weight regain

April 18, 2025

Study details: This single-center retrospective observational study evaluated the efficacy and safety of 12-month therapy with GLP-1 RAs, liraglutide and semaglutide, in patients experiencing weight regain after bariatric surgery. Forty patients (80% female) were included, with treatments initiated approximately 74.5 months post surgery.

Results: After 12 months of GLP-1 RA treatment, significant reductions in total body weight, BMI, and percentage excess body weight were observed. Patients experienced a median weight loss of 10.5 kg, BMI reduction of 3.7 kg/m², and loss of 99.3% of the weight regained. Semaglutide showed greater efficacy in BMI reduction compared with liraglutide. Mild and transient adverse events were reported in 32.5% of patients.

Clinical impact: The GLP-1 receptor agonists, liraglutide and semaglutide, are effective and safe options for managing weight regain in post-bariatric surgery patients. Their use could enhance long-term weight maintenance and improve health outcomes in this population.

Source:

Jensen AB, et al. (2025, April 7). BMC Endocr Disord. Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study. https://pubmed.ncbi.nlm.nih.gov/40197361/